
This version is available at https://strathprints.strath.ac.uk/56129/

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk

The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde's intellectual output.
Title: Impact of partial bivalent HPV vaccination on vaccine-type infection; a population-based analysis

K Cuschieri1&3, K Kavanagh2, C Moore1, R Bhatia3, J Love4 and KG Pollock.4

1: Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Scotland, EH16 4SA
2: Department of Mathematics and Statistics, Strathclyde University, 26 Richmond Street, Glasgow, Scotland, G1 1XH
3: HPV Research Group, Queens Medical Research Institute, University of Edinburgh, Scotland, EH16 4TJ
4: Health Protection Scotland, Meridian Court, Glasgow, Scotland, G2 6QE

Running Title: Effect of partial vaccination on HPV prevalence

Corresponding author: Kate Cuschieri, Director - Scottish HPV Reference Laboratory, Division of Lab Medicine, Royal Infirmary of Edinburgh EH16 4SA.

Tel: 0131 242 6039.
Fax: 0131 242 6008.
Email: Kate.Cuschieri@luht.scot.nhs.uk
ABSTRACT

Background: Data on the effectiveness of 1 dose of HPV vaccine are lacking, particularly in population-based settings. Data from a national HPV immunisation catch-up programme of 14-18 year old girls were used to assess the effectiveness of < 3 doses of the bivalent vaccine on vaccine-type and cross reactive-type HPV infection.

Methods: Cervical samples from women attending for their first cervical smear which had been genotyped for HPV as part of a longitudinal HPV surveillance programme were linked to immunisation records to establish the number of vaccine doses (0,1,2,3) administered. Vaccine effectiveness (VE) adjusted for deprivation and age at first dose, was assessed for prevalent HPV 16/18 and HPV 31/33/45 infection.

Results: VE for prevalent HPV 16/18 infection associated with 1, 2 and 3 doses was 48.2% (95% CI 16.8-68.9), 54.8% (95% CI 30.7-70.8) and 72.8% (95% CI 62.8-80.3). Equivalent VE for prevalent HPV 31/33/45 infection was -1.62% (95% CI -85.1 - 45.3), 48.3 % (95% CI 7.6 -71.8) and 55.2 % (95% CI 32.6-70.2).

Conclusion: Consistent with recent aggregated trial data, we demonstrate the potential effectiveness of even one dose of HPV vaccine on vaccine type infection. Given that these women were immunised as part of a catch-up campaign, the VE observed in this study is likely to be an underestimate of what will occur in girls vaccinated at younger ages. Further population-based studies which look at the clinical efficacy of one dose schedules are warranted.
INTRODUCTION

There is now overwhelming global evidence to demonstrate that the licensed bivalent and quadrivalent Human Papillomavirus (HPV) vaccines are highly efficacious for the prevention of HPV infection and associated disease when administered as a 3 dose schedule. However, as described more recently, a 2 dose schedule with an extended interval between doses 1 and 2 has also been demonstrated to be efficacious (Drolet et al, 2015, Lowy et al, 2015). The move to a 2 dose schedule offers clear cost and logistic advantages. However, the data on the efficacy of 1 dose is relatively sparse. Given that the majority of countries where HPV vaccine is needed most, view national immunisation programmes as cost-prohibitive, the case and potential effectiveness for 1 dose schedules requires further investigation. In a recent article by Kreimer et al (2015) which used combined data from the Costa Rica Vaccine Trial (CVT) and PATRICIA, the authors showed that 4 years after women aged 15-25 were vaccinated with the bivalent vaccine, one dose (and two doses administered at 0 and 1 months) provided significant protection against HPV16/18 infection.

In Scotland, females aged 12-13 have received HPV vaccine at school since 2008 with an initial 3 year “catch-up” for females aged 14-17 years and 364 days. Since 2011, catch-up females have entered the Scottish cervical screening programme (SCSP), which first invites women from the age of 20. Longitudinal surveillance of vaccine impact on HPV infection and disease is possible as vaccine status - including number of doses - can be linked to a cervical screening record and a significant impact of 3 doses of the bivalent vaccine on both HPV infection and associated disease has been observed (Kavanagh et al 2013 & 14, Pollock et al 2014). Our aim in the present analysis, by supplementing our standard surveillance with additional sampling of those vaccinated with 1 and 2 doses, was to assess vaccine effectiveness (VE) on prevalent HPV infection in women who received < 3 doses of the bivalent vaccine, thereby complementing the trial-based work of Kreimer and colleagues with a population-based analysis.

MATERIALS AND METHODS

Overview of Epidemiology and Surveillance Programme and derivation of sample set

The overarching structure of the HPV Immunisation programme in Scotland and the associated Scottish epidemiology and surveillance programme has been described elsewhere (Kavanagh et al 2013, Kavanagh et al 2014). Briefly, one aspect of the surveillance programme
involves monitoring of HPV infection in women attending for first smear. Since 2009 a yearly tranche of ~2000 residual cervical cytology samples from women (attending for first smear) has been collated from all NHS cytopathology laboratories that serve the SCSP. Collated samples were subject to HPV genotyping by the Optiplex HPV genotyping assay (Diamex, Heidelberg, Germany) which can delineate 24 HPV types including all established high-risk types. All residual samples are stored in the Scottish HPV Archive, a national repository and “collection of collections” of cervical samples for use in research [http://www.shine.mvm.ed.ac.uk/archive.shtml](http://www.shine.mvm.ed.ac.uk/archive.shtml). Linkage of the sample through a cervical screening record to vaccination status, including number of doses was made through use of a unique identifier. The present analysis was designed specifically to report on the impact of < 3 doses of vaccine on prevalent HPV infection and represents one of several pieces of work performed in Scotland designed to look at the impact of vaccine on various outcomes including - infection (Kavanagh et al 2014, Bhatia et al 2015), histological abnormalities (Pollock et al 2014) cytology performance (Palmer et al 2016a) and) screening uptake (Palmer et al 2016b)

**Detail of Sample set used for <3 dose analysis**

Analysis was based on women who had received vaccine as part of a catch-up programme that ran for girls up to age 17 years and 364 days (women born in 1988-1993). As described above, for standard immunisation surveillance in Scotland, ~2000 samples are collated and from all laboratories that serve the Scottish Cervical Screening Programme (proportionate to their remit) and stored, of which ~ 1000 geographically representative samples are genotyped. Table 1 shows overall demographics of the population tested for the present analysis stratified by vaccine status. To boost the number of samples from women who received < 3 doses, all additional stored samples (n=234) associated with < 3 doses collected from women both in 1988-1993 were also tested. Thus, the final analysis incorporated a total of 300 samples from women who had received 2 doses, generally administered at 0 and 1 month(s), whereas 177 had received 1 dose only. This compared to 1853 that had 3 doses of vaccine over the same time frame. As the unvaccinated group necessarily incorporated older birth cohorts, adjustments for birth cohort and age at receipt of vaccine were made (see below)
Analysis - vaccine effectiveness

To estimate vaccine effectiveness, the adjusted odds ratio (OR) of prevalent infection with both HPV 16/18 and HPV 31/33/45 (in aggregate) for 1, 2, and 3 doses of vaccination was estimated using logistic regression by comparing to the unvaccinated group and VE calculated as 100*(1-OR). The odds of HPV infection was adjusted for deprivation through use of the Scottish Index of Multiple Deprivation Score (SIMD), birth cohort (to account for any potential temporal changes in HPV prevalence) and age at receipt of first dose for those vaccinated, as those who were vaccinated at older ages - and therefore outside the schools based programme – were more likely to have received < 3 doses. VE for women who received 3 doses over the same time frame is presented for context and comparison.

RESULTS

HPV prevalence in women with 0, 1, 2 and 3 doses of vaccine – unadjusted analysis

Table 2 shows the prevalence of HPV 16/18 and HPV 31/33/45 stratified according to number of vaccine doses. Prevalence of HPV 16/18 was highest in women who received 0 doses of vaccine (29.3%) and lowest in those who received 3 doses (11.0%) – comparatively those who had one and two doses of vaccine had significantly lower prevalence(s) of HPV 16/18: 23.7% (95% CI 18.1, 30.5) and 21.0% (95% CI 16.8, 26.0) respectively when compared to those who had 0 doses. Prevalence of HPV 31/33/45 was no different in women who received 0 or 1 dose of vaccine: 12.9% (95% CI 11.9, 14.1) and 14.7% (95% CI 10.2, 20.7) respectively but was lower in those who received 2 and 3 doses: 8% (95% CI 5.4, 11.6) and 6.2% (95% CI 5.2, 7.4) respectively.

The univariate analysis showed the odds of infection with HPV 16/18 in women vaccinated with 1, 2 and 3 doses (compared to 0 doses) were 0.75 (0.52, 1.06) 0.64 (95% CI 0.48, 0.85) and 0.30 (95% CI 0.25, 0.35), respectively. Comparative odds for HPV 31/33/45 infection were 1.16 (95% CI 0.74, 1.75), 0.59 (95% CI 0.37, 0.88), and 0.45 (95% CI 0.36, 0.55).

Vaccine effectiveness in women with < 3 doses of vaccine

Table 3 presents VE for prevalent infection with HPV 16/18 and HPV 31/33/45, adjusted for age at first vaccination and SIMD. VE for prevalent HPV 16/18 infection associated with 1, 2
and 3 doses was 48.2% (95% CI 16.8-68.9), 54.8% (95% CI 30.7-70.8) and 72.8% (95% CI 62.8-80.3). Equivalent VE for prevalent 31/33/45 infection associated with 1, 2 and 3 vaccine doses was -1.62% (95% CI -85.1 - 45.3), 48.3 % (95% CI 7.6 -71.8) and 55.2 % (95% CI 32.6-70.2). Thus, we observed an impact of 1 dose on the prevalence of vaccine-type infection. Furthermore, cross-protection for HPV 31/33/45 with 2 doses was similar to that conferred by 3 doses even though the 2 doses were largely administered at 0 and 1 months (compared with 3 dose schedule of 0, 1 and 6 months).

**DISCUSSION**

Through the assessment of HPV infection in women immunised via a national catch-up programme, we observed an impact of 1 and 2 doses of vaccine on the prevalence of HPV 16/18 infection – albeit lower than that associated with 3 doses. Notably, cross protection for HPV 31/33/45 with 2 doses was similar to that conferred by 3 doses even though the 2 doses were largely administered at 0 and 1 months. Vaccination with 1 dose did not confer a cross protective effect against HPV 31/33/45.

There are caveats to our analysis; as immunisation uptake for the complete schedule has been consistently high in Scotland, relatively few women had < 3 doses (http://www.isdscotland.org/Health-Topics/Child-Health/publications/index.asp.) Consequently, rare outcomes such as mono infection with HPV 31, 33 and 45 are challenging to measure with current numbers. Furthermore, we did not have knowledge of HPV status prior to vaccination and outcomes could not be measured as incident or persistent infection. This is apposite considering that analysis was based on women vaccinated as part of a catch-up programme, so a proportion will have been exposed to HPV, pre-vaccination. In a previous HPV prevalence study in Scotland undertaken prior to the national vaccination programme, which utilised urine, 12.6 % of women aged 15-18 were HR-HPV positive (O’ Leary et al 2011). Consequently, the VE described above is likely to be an underestimate of that expected in HPV-naïve women. In addition we also compared older unvaccinated women with younger vaccinated women, who may have different attitudes and behaviours with respect to health care/screening. In a recent observational study by Palmer et al (2016), uptake of first invitation to cervical screening by vaccine status was assessed; immunised women in the catch-up
cohorts showed higher attendance than unimmunised women, but this may be a result of a greater awareness of health issues and may not be replicated in routinely immunised women.

It is of interest that our overarching observations are consistent with those of Kreimer et al, in spite of the clear differences between settings. Notably, the cross-protective data align more with those of the PATRICIA trial, rather than the combined analysis, which reported a higher 1 dose VE, albeit a non-significant one. This may reflect differences in the individual contribution of HPV 31, 33 and 45 across settings, between-study HPV assay differences or, as indicated earlier, it may simply be an issue of power for this low-frequency outcome.

While an impact of 1 dose was observed, it was lower than that observed with 3 doses. As the bulk of 2 dose data was associated with 0 and 1 month scheduling, we cannot compare 1 dose effectiveness with data that mimic the “extended” 2 dose schedules which is current policy in Scotland and other settings. Nevertheless, the lower effectiveness of 1 dose, may be as a consequence of lower immunogenicity. In a recent study by La Montagne et al (2015) of 376 Ugandan girls aged between 10 and 11 who received 1, 2 and 3 doses of the bivalent vaccine, geometric mean antibody levels (GMTs) measured at 24 months for HPV 16/18 were inferior in women who received 1 dose compared to 3 doses. However, the authors noted that levels were still higher than those observed in adult women who received 1 dose and where efficacy (for infection endpoints) had been demonstrated.10 The authors also contended that the GMTs associated with one dose were higher than those generated as a consequence of natural infection where a partially protective effect had been demonstrated (Safaeian et al 2014).

While we did/could not measure GMTs in the current analysis, given the average age of vaccination was much higher than the Ugandan study, it is tempting to speculate that one dose VE will be higher in the routine (12-13 year old) cohorts given their lower likelihood of being infected before vaccination and an anticipated higher immunogenic response to the vaccine. It will be of interest to see how the VE estimates change when women who were vaccinated as part of the routine (12-13 year old) cohort enter the Scottish screening programme in late 2015.

To conclude, while we do not assert that current data on 1 dose protection are sufficient to influence policy, given that an impact has been observed in trial settings and in this and other population based settings (Brotherton et al 2015) there is now clear evidence to justify further, comprehensive assessment of one dose efficacy, given the global implications.
ACKNOWLEDGEMENTS

We would like to thank all members of the Scottish HPV Reference Laboratory and the HPV Research group for support with sample processing and testing. Thanks are also due to NRS Lothian Bioresource (formerly SAHSC Bioresource) for support with sample capture and governance.
REFERENCES


combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 16: 775-86.


<table>
<thead>
<tr>
<th>Variable</th>
<th>Number</th>
<th>%</th>
<th>Variable distribution (%) in unvaccinated</th>
<th>Variable distribution (%) in 1 dose vaccinated</th>
<th>Variable distribution (%) in 2 dose vaccinated</th>
<th>Variable distribution (%) in 3 dose vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Birth cohort</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1988</td>
<td>838</td>
<td>14.1</td>
<td>23.1</td>
<td>0.6</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>1989</td>
<td>1178</td>
<td>19.8</td>
<td>32.4</td>
<td>1.1</td>
<td>0.7</td>
<td>0.0</td>
</tr>
<tr>
<td>1990</td>
<td>1253</td>
<td>21.1</td>
<td>28.0</td>
<td>19.8</td>
<td>21.0</td>
<td>7.7</td>
</tr>
<tr>
<td>1991</td>
<td>937</td>
<td>15.8</td>
<td>7.8</td>
<td>28.2</td>
<td>34.3</td>
<td>27.1</td>
</tr>
<tr>
<td>1992</td>
<td>1317</td>
<td>22.1</td>
<td>6.9</td>
<td>37.9</td>
<td>32.7</td>
<td>48.7</td>
</tr>
<tr>
<td>1993</td>
<td>426</td>
<td>7.2</td>
<td>1.8</td>
<td>12.4</td>
<td>11.3</td>
<td>16.5</td>
</tr>
<tr>
<td><strong>SIMD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1405</td>
<td>23.6</td>
<td>23.7</td>
<td>31.6</td>
<td>31.0</td>
<td>21.6</td>
</tr>
<tr>
<td>2</td>
<td>1256</td>
<td>21.1</td>
<td>21.1</td>
<td>24.9</td>
<td>27.7</td>
<td>19.7</td>
</tr>
<tr>
<td>3</td>
<td>1131</td>
<td>19.0</td>
<td>19.9</td>
<td>19.2</td>
<td>14.3</td>
<td>18.0</td>
</tr>
<tr>
<td>4</td>
<td>1027</td>
<td>17.3</td>
<td>17.1</td>
<td>14.7</td>
<td>13.0</td>
<td>18.5</td>
</tr>
<tr>
<td>5</td>
<td>1130</td>
<td>19.0</td>
<td>18.2</td>
<td>9.6</td>
<td>14.0</td>
<td>22.2</td>
</tr>
<tr>
<td><strong>Age at vaccine for those vaccinated</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-16</td>
<td>1016</td>
<td>43.6</td>
<td>-</td>
<td>21.5</td>
<td>23.7</td>
<td>48.9</td>
</tr>
<tr>
<td>17</td>
<td>685</td>
<td>29.4</td>
<td>-</td>
<td>29.9</td>
<td>29.3</td>
<td>29.4</td>
</tr>
<tr>
<td>18</td>
<td>461</td>
<td>19.8</td>
<td>-</td>
<td>24.9</td>
<td>30.0</td>
<td>17.6</td>
</tr>
<tr>
<td>Over 18</td>
<td>168</td>
<td>7.2</td>
<td>-</td>
<td>23.7</td>
<td>17.0</td>
<td>4.0</td>
</tr>
</tbody>
</table>

*Table 1:* Overall demographics of the population stratified by vaccine status
Table 2: Prevalence (unadjusted) of vaccine and cross-reactive HPV types according to number of vaccine doses

<table>
<thead>
<tr>
<th>No. of Doses</th>
<th>No. of samples</th>
<th>No. pos 16/18 [% (95 CI’s)]</th>
<th>No. pos 31/33/45 [% (95 CI’s)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>3619</td>
<td>1062 [29.3 (27.9, 30.8)]</td>
<td>468 [12.9 (11.9, 14.1)]</td>
</tr>
<tr>
<td>1</td>
<td>177</td>
<td>42 [23.7 (18.1, 30.5)]</td>
<td>26 [14.7 (10.2, 20.7)]</td>
</tr>
<tr>
<td>2</td>
<td>300</td>
<td>63 [21.0 (16.8, 26.0)]</td>
<td>24 [8.0 (5.4, 11.6)]</td>
</tr>
<tr>
<td>3</td>
<td>1853</td>
<td>203 [11.0 (9.7, 12.5)]</td>
<td>115 [6.2 (5.2, 7.4)]</td>
</tr>
</tbody>
</table>

Table 2: Prevalence (unadjusted) of vaccine and cross-reactive HPV types according to number of vaccine doses